174 related articles for article (PubMed ID: 37689322)
1. Immunosuppressive CD10
Meng Y; Ye F; Nie P; Zhao Q; An L; Wang W; Qu S; Shen Z; Cao Z; Zhang X; Jiao S; Wu D; Zhou Z; Wei L
J Hepatol; 2023 Dec; 79(6):1435-1449. PubMed ID: 37689322
[TBL] [Abstract][Full Text] [Related]
2. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
3. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. S100A9
Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
[TBL] [Abstract][Full Text] [Related]
6. A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.
Su X; Yin H; Bai M; Liu J; Liu R; Zeng H; Wen J
J Immunol; 2023 Mar; 210(5):681-695. PubMed ID: 36602827
[TBL] [Abstract][Full Text] [Related]
7. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
8. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
[TBL] [Abstract][Full Text] [Related]
9. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
10. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
12. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
[TBL] [Abstract][Full Text] [Related]
13. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
14. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
16. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
17. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
19. Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer.
Feng M; Wang F; Liu X; Hao T; Zhang N; Deng M; Pan Y; Kong R
Cancer Biol Med; 2023 May; 20(6):421-37. PubMed ID: 37184030
[TBL] [Abstract][Full Text] [Related]
20. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
